RADEK SKODA to Female
This is a "connection" page, showing publications RADEK SKODA has written about Female.
Connection Strength
0.428
-
MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020 11 26; 136(22):2591-2595.
Score: 0.027
-
A Gain-of-Function Mutation in EPO in Familial Erythrocytosis. N Engl J Med. 2018 03 08; 378(10):924-930.
Score: 0.022
-
Mutational profile of childhood myeloproliferative neoplasms. Leukemia. 2015 Dec; 29(12):2407-9.
Score: 0.018
-
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014 Oct 20; 211(11):2213-30.
Score: 0.017
-
Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014 Jun 19; 123(25):3943-50.
Score: 0.017
-
Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2744-5.
Score: 0.017
-
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 03; 123(14):2220-8.
Score: 0.017
-
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia. Blood. 2013 Nov 21; 122(22):3694-6.
Score: 0.016
-
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013 Feb 14; 121(7):1188-99.
Score: 0.015
-
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010 Mar 11; 115(10):2003-7.
Score: 0.013
-
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009 Oct; 94(10):1368-74.
Score: 0.012
-
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009 Feb 26; 113(9):2022-7.
Score: 0.012
-
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008 Dec; 93(12):1890-3.
Score: 0.011
-
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. Haematologica. 2008 May; 93(5):706-14.
Score: 0.011
-
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood. 2008 Apr 01; 111(7):3863-6.
Score: 0.011
-
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008 Jan; 93(1):34-40.
Score: 0.011
-
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007 Jul 01; 110(1):375-9.
Score: 0.010
-
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006 Aug 15; 108(4):1377-80.
Score: 0.010
-
Chronic myeloproliferative disorders--introduction. Semin Hematol. 2005 Oct; 42(4):181-3.
Score: 0.009
-
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005 Nov 15; 106(10):3374-6.
Score: 0.009
-
Identification of Hepatic-like EPO as a Cause of Polycythemia. N Engl J Med. 2025 May 01; 392(17):1684-1697.
Score: 0.009
-
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28; 352(17):1779-90.
Score: 0.009
-
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. Leukemia. 2025 May; 39(5):1135-1145.
Score: 0.009
-
Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia. Br J Haematol. 2000 Jul; 110(1):104-9.
Score: 0.006
-
Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol. 2000 Jun; 79(6):312-8.
Score: 0.006
-
Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020 04 30; 135(18):1548-1559.
Score: 0.006
-
Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol. 1999 Nov; 107(2):310-6.
Score: 0.006
-
Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans. Nat Commun. 2019 03 19; 10(1):1252.
Score: 0.006
-
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica. 2019 04; 104(4):710-716.
Score: 0.006
-
HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat Commun. 2018 04 12; 9(1):1431.
Score: 0.006
-
An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998 Jan; 18(1):49-52.
Score: 0.005
-
Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. Biomed Res Int. 2017; 2017:9876819.
Score: 0.005
-
Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Ann Hematol. 2017 Mar; 96(3):393-404.
Score: 0.005
-
Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. Leukemia. 2017 03; 31(3):759-762.
Score: 0.005
-
Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. Mol Carcinog. 2017 02; 56(2):567-579.
Score: 0.005
-
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4642-7.
Score: 0.004
-
Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. 2014 Dec; 12(12):2120-30.
Score: 0.004
-
Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thromb Haemost. 2015 Feb; 113(2):414-25.
Score: 0.004
-
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 07; 512(7512):78-81.
Score: 0.004
-
Dkk3 levels in patients with myeloproliferative neoplasms. Thromb Res. 2014 Feb; 133(2):218-21.
Score: 0.004
-
Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood. 2011 Sep 29; 118(13):3670-9.
Score: 0.003
-
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011 Mar 10; 117(10):2813-6.
Score: 0.003
-
Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol. 2009 Jul; 146(2):150-7.
Score: 0.003
-
Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A. 1988 Jul; 85(14):5240-3.
Score: 0.003
-
NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? Leukemia. 2008 Jul; 22(7):1459-63.
Score: 0.003
-
Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med. 2007 Dec 24; 204(13):3103-11.
Score: 0.003
-
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008 Feb 01; 111(3):1686-9.
Score: 0.003
-
Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood. 2007 Nov 01; 110(9):3183-91.
Score: 0.003
-
[Immuneglobin-D-serum level with healthy test persons and patients with diseases of the respiratory tract (author's transl)]. Laryngol Rhinol Otol (Stuttg). 1978 Sep; 57(9):850-6.
Score: 0.001
-
The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Br J Haematol. 1998 Sep; 102(5):1341-3.
Score: 0.001